title: Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial.
abstract: OBJECTIVE
  This study sought to evaluate the antiarrhythmic effects of lipid-lowering drug therapy as assessed by ventricular tachyarrhythmia (ventricular tachycardia [VT]/ventricular fibrillation [VF]) recurrences recorded by an implantable cardioverter defibrillator (ICD) in patients with atherosclerotic heart disease (ASHD).
  
  
  BACKGROUND
  Randomized trials of lipid-lowering drugs suggest reduction of sudden death (SD) in patients with ASHD. Because SD is usually secondary to VT/VF, this observation suggests that lipid-lowering therapy has antiarrhythmic effects.
  
  
  METHODS
  The probability of VT/VF recurrence in patients with ASHD treated with an ICD in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial who did not receive lipid-lowering drug therapy (n = 279) was compared with that in patients who received early and consistent lipid-lowering therapy (n = 83). In addition, all-cause mortality and cardiac mortality of all patients in the AVID trial with ASHD who did not receive lipid-lowering therapy (n = 564) were compared with that of those who received early and consistent lipid-lowering therapy (n = 149).
  
  
  RESULTS
  Using multivariate analyses, lipid-lowering therapy was associated with a reduction in the relative hazard for VT/VF recurrence of 0.40 (95% confidence interval [CI] 0.15 to 0.58) (adjusted p = 0.003) in the ICD subgroup. Lipid-lowering therapy was also associated with a reduction in the relative hazard for all-cause mortality of 0.36 (95% CI 0.15 to 0.68) (adjusted p = 0.03) and a reduction in the relative hazard for cardiac mortality of 0.39 (95% CI 0.16 to 0.78) (adjusted p = 0.04) in the larger study population.
  
  
  CONCLUSIONS
  In patients with ASHD who have received an ICD, lipid-lowering therapy is associated with reduction in the probability of VT/VF recurrence, suggesting that part of the benefit of lipid-lowering therapy may be due to an antiarrhythmic effect.
authors.affiliation: Division of Cardiology, Foothills Hospital/University of Calgary, 1403 29th Street NW, Calgary, Alberta, Canada T2N 2T9. brent.mitchell@calgaryhealthregion.ca
authors.forename: L Brent
authors.initials: LB
authors.lastname: Mitchell
authors.forename: Judy L
authors.initials: JL
authors.lastname: Powell
authors.forename: Anne M
authors.initials: AM
authors.lastname: Gillis
authors.forename: Victoria
authors.initials: V
authors.lastname: Kehl
authors.forename: Alfred P
authors.initials: AP
authors.lastname: Hallstrom
mesh_terms: D000368:Aged; D003324:Coronary Artery Disease / Q000188:drug therapy*; D017147:Defibrillators, Implantable; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D055502:Secondary Prevention; D016019:Survival Analysis; D017180:Tachycardia, Ventricular / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control / Q000628:therapy*; D014693:Ventricular Fibrillation / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control / Q000628:therapy*
chemical_list: D000960:Hypolipidemic Agents